When it comes to pre-revenue biotechs, it's often a struggle to build an investment thesis beyond "if the medicine works, the ...
The company's latest presentation supports the idea that its lead program will make billions.
The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...
Similar adverse events as those seen with other GLP-1 receptor agonists were reported. The Company is also evaluating an oral tablet formulation of VK2735 (ClinicalTrials.gov Identifier: NCT05203237).
Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...
Novo Nordisk reports earnings Wednesday morning, with sales of blockbuster weight-loss drugs Ozempic and Wegovy expected to continue driving the Danish drugmaker's results higher.
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight ...
Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from ...
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's ...